A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer Background: Paclitaxel-carboplatin is used as the standard regimen for patients with advanced or metastatic nonsmall-cell lung cancer (NSCLC). This trial was designed to compare gemcitabine + carboplatin or gemcitabine + paclitaxel to the standard regimen. Results: Median survival (months) with GC was 7.9 compared with 8.5 for GP and 8.7 for PC. Response rates (RRs)
introduction
The annual burden of non-small-cell lung cancer (NSCLC) was estimated in 2007 at 181 000 new cases and 136 000 deaths in the United States [1] . At the time of diagnosis, most patients (>80%) have locally advanced stage III or metastatic stage IV disease and are ineligible for potentially curative surgery; and 5-year survival is <10% in this patient population [2, 3] . Palliative chemotherapy has become the standard therapy for patients with advanced NSCLC, with platinum-based doublets producing a modest survival benefit and improvement in quality of life compared with best supportive care alone [4] [5] [6] [7] .
Several large randomized trials that have compared commonly prescribed platinum doublets did not support any specific regimen as the evidenced-based practice standard for NSCLC [8] [9] [10] [11] . Studies indicate non-platinum doublets can also provide benefits similar to platinum doublets [12, 13] .
Paclitaxel produces single-agent response rates (RRs) between 20% and 42%, with 1-year survival rates of 40% in advanced NSCLC [14] [15] [16] . Eastern Cooperative Oncology Group (ECOG) 5592 formed the basis for paclitaxel + cisplatin use in advanced NSCLC by demonstrating a median survival of 9.9 months in association with this combination (at two dose levels of paclitaxel) compared with 7.6 months with etoposide + cisplatin [17] . Concerns over cisplatin-related neurotoxicity led to the eventual replacement of cisplatin with carboplatin within platinum-based treatment regimens [18, 19] .
As a single agent in advanced NSCLC, gemcitabine has produced RRs between 20% and 28% and survival between 7 and 11 months [20] [21] [22] [23] . In combination with gemcitabine, platinum combination regimens have resulted in RRs between 28% and 54% and 1-year survival rates between 35% and 61%, with manageable toxicity [24] [25] [26] . Gemcitabine and paclitaxel have shown single-agent activity in advanced NSCLC, lack overlapping toxic effects, and have different mechanisms of action [27] . Trials of the combination of gemcitabine and paclitaxel have resulted in RRs between 27% and 47%, with manageable toxicity [28] [29] [30] [31] . Several phase II studies have tested the combination of gemcitabine + carboplatin, demonstrating levels of activity similar to other combinations [32] [33] [34] .
Given the similarity of response of gemcitabine + paclitaxel to most platinum-containing regimens, the toxicity profile could determine the choice of first-line regimen for future evaluation of chemotherapeutic approaches for advanced or metastatic NSCLC. Therefore, a prospective, randomized comparison of overall survival (OS), efficacy, and toxicity was conducted to determine the role of non-platinum-and nonpaclitaxel-containing regimens in the treatment of NSCLC. In this phase III study, paclitaxel + carboplatin (PC) was chosen as the reference regimen for comparison with either gemcitabine + carboplatin (GC) or gemcitabine + paclitaxel (GP), with the goal of identifying the regimen associated with the best therapeutic index.
patients and methods

study design
Patients with stage IIIB (with pleural or pericardial effusion), stage IV, or recurrent NSCLC who met all eligibility criteria were randomly allocated to receive one of the three treatment regimens as summarized in Figure 1 . Patient stratification by baseline weight loss (<5% versus ‡5% in previous 6 months), stage of disease (IIIB with effusion versus IV), and brain metastasis (presence versus absence) took place at the time of randomization to ensure balance across treatment arms with respect to these characteristics. Patients were randomly allocated to receive one of the three platinum or non-platinum regimens in equal proportions as follows-arm A: gemcitabine 1000 mg/m 2 infused over 30 min on days 1 and 8 plus carboplatin AUC 5.5 over 15-30 min on day 1 (GC); arm B: gemcitabine 1000 mg/m 2 infused over 30 min on days 1 and 8 plus paclitaxel 200 mg/m 2 infused over 3 h on day 1 (GP); or arm C: paclitaxel 225 mg/m 2 infused over 3 h on day 1 plus carboplatin AUC 6.0 over 15-30 min on day 1 (PC). Treatment cycles for all three treatment arms were repeated every 21 days for six cycles or until unacceptable toxicity or disease progression. Carboplatin dosing was based on the formula described by Calvert et al. [35] . Guidelines for dose adjustments were provided for chemotherapy-related hematologic, gastrointestinal, cardiovascular, or hepatic toxicity. In arm A, patients with ‡20% of bone marrow previously irradiated received a reduced dose of carboplatin (AUC 5.0). In arms B and C, patients received prophylactic dexamethasone 20 mg orally 12 and 6 h before paclitaxel infusion, diphenhydramine 50 mg i.v. (or equivalent) £1 h before paclitaxel infusion, and cimetidine 300 mg i.v. (or equivalent; ranitidine 50 mg or famotidine 20 mg) £1 h before paclitaxel infusion. Patients who developed brain metastases as the only evidence of progressive disease (PD) were able to be treated with whole-brain radiation and corticosteroids for brain metastases and remain on study. Chemotherapy was resumed 2 weeks after the completion of brain irradiation. However, if the patient's condition did not recover to an ECOG performance status of zero or one or the patient failed to meet other entry criteria after radiation therapy, the patient was removed from the study. No other chemotherapy, immunotherapy, antitumor hormonal therapy (excluding contraceptives and replacement steroids), or experimental medication was permitted while the patient was on the study and appropriate supportive care was provided. Granulocyte colony-stimulating factors (G-CSF) were only allowed if there was persistent neutropenia despite dose reductions in the previous course. If G-CSF were used, it was in accordance with American Society of Clinical Oncology (ASCO) guidelines [36] .
patient selection
Patients with a histologically confirmed diagnosis of stage IIIB (with pleural or pericardial effusion), stage IV, or recurrent NSCLC were enrolled in this study [37] . Mixed tumors were categorized by the predominant cell type unless small-cell anaplastic elements were present, in which case the patient was ineligible. All patients were required to be ‡18 years of age and have measurable or evaluable disease (according to ECOG solid tumor criteria); an ECOG performance status of zero or one; and adequate bone marrow reserve (neutrophils >1500/mm 3 , platelets >100 000/mm 3 ), adequate hepatic function [aspartate transaminase £5· institutional upper limit of normal (ULN) and serum bilirubin £1.5 mg/dl· institutional ULN], and adequate renal function (creatinine clearance ‡40 ml/min or serum creatinine £1.5 mg/dl). Stage IV patients with brain metastases were eligible provided the brain metastases were, in the opinion of the site investigator, clinically stable after treatment with surgery or radiation therapy.
No previous irradiation to the only area of measurable or evaluable disease was allowed, unless that site had subsequent progression of disease documented by physical examination, radiograph, or pathology. Patients receiving prior chemotherapy for this diagnosis were excluded from participation. Pregnant or breast-feeding women were not eligible, and all women of childbearing potential and sexually active men were required to use an approved method of birth control. Patients with a known or suspected hypersensitivity to agents that utilize polyoxyethylated castor oil were excluded from participation.
This study was reviewed and approved by an ethical review board at each participating institution, and it was conducted in accordance with the precepts established by the Declaration of Helsinki. Patients who were eligible for participation provided written informed consent consistent with all applicable governing regulations before undergoing any study procedure or receiving any study drug.
statistical analysis
The primary end point of this trial was OS. Secondary end points included RRs, time to progression (TTP), and tolerability as assessed by adverse event reporting. Three pairwise comparisons of OS (GC versus GP, GC versus PC, and GP versus PC) were done with a modified Bonferroni adjustment to control for multiplicity [38] . All tests were two sided [39] . To ensure an overall significance level of 0.05, the nominal significance level was set at one-sided 0.0083 for all three adjusted log-rank test comparisons (an one-sided 2.5% significance level is equivalent to a two-sided test at the 5% significance level). To detect a 33.3% increase in median survival between two arms with 83% power, 1080 patients (360 patients per arm) accrued in a 24-month period with 12 months of additional follow-up were required. Assuming a patient drop-out rate of 5%, sample size for the study was set at 1134 patients. Survival and TTP were assessed using the intention-to-treat (ITT) population and calculated from the date of randomization to the date of death or documented progression. Survival and TTP curves were constructed using the Kaplan-Meier product limit method [40] . Standard ECOG criteria were used for response evaluation [41] . Complete clinical response was defined as the radiographic disappearance of all known disease, determined by two observations not less than 4 weeks apart. Tumor measurement occurred at baseline, before each chemotherapy cycle, and every 3 months during the follow-up period. Partial response (PR) was defined as a ‡50% decrease in bidimensional measurements of the target lesions confirmed by two observations ‡4 weeks apart. In addition, there had to be no appearance of new lesions or progression of any lesion. PD was ‡25% increase in the bidimensional measurements of at least one measurable lesion or the appearance of new lesions. RRs were calculated by summing the number of patients with complete responses (CRs) and PRs, and clinical benefit rates were calculated by summing the number of patients with CRs, PRs, and stable disease (SD). Safety of the treatment regimens was assessed by calculating the percentage of patients experiencing grade 3 or 4 toxic effects using National Cancer Institute (NCI) Common Toxicity Criteria version 2.0 [42] . Only patients receiving at least one dose of treatment were included in the safety population. Additional analyses of patient subgroups and quality-of-life outcomes using the Functional Assessment of Cancer Therapy-Lung tool were planned [43] .
results Figure 2 summarizes patient disposition in the trial. From July 2000 to November 2005, 1135 patients were screened for eligibility/entry and were randomly assigned to one of the three treatments: GC (N = 379), GP (N = 377), or PC (N = 379), at 80 investigative centers. Of these 1135 patients, 58 (5.1%) did not receive any study therapy; thus, 1077 patients are included in the safety analysis population.
patient characteristics
As shown in Table 1 , patient characteristics for the ITT population at baseline were well balanced across the three treatment groups. The median age of patients in the ITT population was 64.3 years. Most patients in all arms were male and had an ECOG performance status of one. Within the ITT population, 17.1% had brain metastases and 12.2% were African-American. Ninety percent of patients in all treatment groups had stage IV or recurrent disease, and 17.8% of patients in all treatment groups had squamous histology.
dose administration
The number of treatment cycles administered did not vary by treatment group. The median number of cycles administered was 4 in all three treatment groups, and the mean number of cycles administered for GC, GP, and PC was 3.9, 3.8, and 3.7, respectively. The percentage of patients receiving a maximum six cycles of therapy was 36.5%, 35.2%, and 30.6% for GC, GP, and PC, respectively. Median relative dose intensity was 82.9% for gemcitabine and 94.6% for carboplatin in the GC arm, 94.9% for gemcitabine and 99.1% for paclitaxel in the GP arm, and 98.2% for paclitaxel and 95.2% for carboplatin in the PC arm. The percentage of patients receiving dose adjustments by treatment was 75.8% for gemcitabine and 62.1% for carboplatin in the GC group, 47.6% for gemcitabine and 31.3% for paclitaxel in the GP group, 32.2% for paclitaxel and 33.9% for carboplatin in the PC group. During therapy, original article Annals of Oncology the rates of discontinuation due to excessive complication or toxicity were 12.4% for GC, 14.1% for GP, and 15.3% for PC. The rates of death without evidence of PD were 4.2% for GC, 4.5% for GP, and 4.2% for PC.
efficacy
Primary efficacy outcomes by treatment group are summarized in Table 2 . Length of median follow-up was 8.2 months, and censorship was low for OS (8.9%) and TTP (7.1%) variables. Curves for OS and TTP are summarized in Figure 3 . Median survival was 7.9 months for GC [95% confidence interval (CI) 7.1-9.2], 8.5 months for GP (95% CI 7.6-10.0), and 8.7 months for PC (95% CI 7.7-9.9). P values for comparisons between individual treatment groups indicated that differences were not statistically significant (GC versus GP, 0.585; GP versus PC, 0.404; and GP versus PC, 0.849), and the P value for the overall comparison was 0.693.
Survival rates at 1 year ranged from 33.9% for GC to 36.2% for GP. Survival rates at 2 years ranged from 11.5% for GC to 13.9% for GP. Survival rates at 3 years ranged from 5.0% for GP to 7.3% for PC. Median TTP (months) for GC, GP, and PC, respectively, was 4.3 (95% CI 4.1-5.1), 4.5 (95% CI 4.0-5.4), and 4.7 (95% CI 4.2-5.5). Differences across treatment arms in TTP were not statistically significant.
Overall RRs (CRs + PRs) were 25.3% for GC, 32.1% for GP, and 29.8% for PC. Although GC was associated with the smallest RR among the treatment groups, it was also associated with an SD rate of 39.3%, which was 8% greater than that of GC, gemcitabine + carboplatin; N, number of patients; GP, gemcitabine + paclitaxel; PC, paclitaxel + carboplatin; n, number in group; CR, complete response; PR, partial response; CI, confidence interval; SD, stable disease; OS, overall survival; TTP, time to progression. Annals of Oncology original article the other two groups. As a result, the clinical benefit rates of all treatment arms were similar and exceeded 60%.
toxicity Grade 3 and 4 hematologic and non-hematologic events are summarized in Table 3 . The frequency of grade 3 and 4 hematologic events was greater for GC compared with the other two treatment arms. The grade 3 or 4 neutropenia rate was 39.0% for GC and 34.7% for PC, compared with 20.0% for GP. The grade 3 thrombocytopenia rate was 49.7% for GC compared with 4.8% for GP and 10.9% for PC. The grade 4 thrombocytopenia rate was 14.9% for GC, compared with 0% for GP and 1.9% for PC. The grade 3 or 4 anemia rate was 23.3% for GC, compared with 4.2% for GP and 6.0% for PC. The GC arm was associated with less grade 2 alopecia compared with the other two treatment groups (13.5% with GC compared with 52.7% each in the other two groups). The incidence of grade 3 or 4 sensory neuropathy was 2.0% for GC, compared with 6.5% for GP and 10.9% for PC.
additional analyses
The large numbers of patients accrued in this study allowed for statistical analyses of outcomes by specific patient subgroups. These analyses were previously presented as abstracts at the 2007 ASCO Annual Meeting. Notably, OS, RRs, and TTP did not differ among patients stratified by age (>70 or <70 years) [44] or by race [45] .
discussion
This prospective, randomized trial, which represents the largest study to date using carboplatin and non-platinum-based doublets, indicates that all three regimens produced similar efficacy in terms of OS, RR, and TTP. Results from this study are largely consistent with other trials comparing doublet original article Annals of Oncology therapies [9, 11, 12, 15] and with ASCO guidelines, which indicate that decisions with respect to chemotherapy choice in the first-line setting should be made largely on the basis of the toxicity profile and convenience of the drugs [46] . In one phase III trial (N = 512) reported by Kosmidis et al., median survival was 9.97 for GP and 10.49 for GC, which was not statistically different between groups. The two arms had toxicity profiles that were consistent with results from the current study [9] . In a second phase III trial of platinum and non-platinum doublets (N = 441), gemcitabine-docetaxel and gemcitabine-cisplatin had similar activity and OS; however, the non-platinum doublet had a more favorable toxicity profile [47] . It should also be noted that recent meta-analyses have indicated higher response [48] and survival rates [48] [49] [50] with third-generation regimens using cisplatin versus carboplatin in patients with advanced disease.
Differences that emerged in this trial were related to the toxicity profiles of the treatment regimens studied. The reference arm (PC) demonstrated more neurotoxicity and alopecia, while the GC arm was associated with greater myelosuppression and reduced median dose intensity. The carboplatin dose used in the GC arm was higher than in more recent trials and this is reflected in the myelosuppressive profile. An analysis of 1126 patients receiving first-line GC in randomized trials (including the current study) found that patients receiving carboplatin at AUC 5 experience approximately one-half the incidence of grade 4 neutropenia and thrombocytopenia compared with patients receiving carboplatin at AUC 5.5, without compromising clinical activity [51] . It is noted that even with the higher dose of carboplatin as used in this trial, there were no differences in the rates of bleeding, which were very low in all three arms. The fatal toxicity rate was also very low across all three arms and consistent with modern doublets in the phase III setting.
While the non-platinum doublet provided similar efficacy outcomes to the platinum-containing arms, the toxicity profile of this particular non-platinum doublet offered no clear advantages. However, other non-platinum doublets containing different agents may offer advantages in terms of toxicity. The role of non-platinum doublets is likely to increase with emerging treatment strategies, particularly in genomically selected therapy, such as the recent development and acceptance of trial designs with molecular markers that predict for platinum resistance [52] [53] [54] . As molecular profile data increase, variations in the efficacy and toxicity of commonly used agents will increase and likely lead to more selected therapy.
While future trials are likely to look at genomic concerns, many trials have reported on more general factors, such as age and ethnicity. The percentage of African-Americans enrolled in this trial compares favorably to historical rates of accrual to lung cancer trials sponsored by the NCI [55] . A separate report from this trial will follow that will look at detailed outcomes in this generally underrepresented population.
The use of PC as the reference arm for this study was supported by the results of ECOG 5592, which showed that paclitaxel + cisplatin was superior to etoposide + cisplatin [17] and several subsequent phase III trials that established the use of PC in advanced or metastatic NSCLC [11, [56] [57] [58] . Compared with ECOG 5592, the survival results in all three arms in the current study surpassed the 7.6-month median survival of the etoposide + cisplatin arm, but were less than the 9.9-month median survival of the 250 mg/m 2 PC arm [17] . Importantly, ECOG 5592 excluded patients with brain metastases, and <80% of patients receiving paclitaxel in ECOG GC, gemcitabine + carboplatin; N, number of patients; GP, gemcitabine + paclitaxel; PC, paclitaxel + carboplatin; n, number in group.
Annals of Oncology original article 5592 had stage IV disease compared with 90% of patients in the current study. An unexpected observation was the relatively high incidence of brain metastases (17.1% overall) seen in this trial. A limited number of randomized phase III studies of advanced or metastatic NSCLC have included a mixed population of patients with and without brain metastases at presentation. Analyses of patients with lung cancer from the 1970s and 1980s indicated that the incidence of brain metastases at the time of diagnosis was 10% [59, 60] . The higher incidence observed in this trial may be related to the increasing incidence of adenocarcinoma, which is more prone to presentation with brain involvement at time of diagnosis [61] . It is also possible that the increased incidence of BM observed in this trial may have been related to the exclusion of these patients in other first-line trials. None the less, with the increasing sensitivity of imaging modalities and the potential for excluding a current therapeutic choice in advancedstage NSCLC, the management of patients with brain metastases may be an issue of growing importance. Doublet chemotherapy will remain foundational for the treatment of advanced or metastatic NSCLC. Numerous combination regimens have been evaluated for this disease in the setting of large phase III trials. This randomized study reiterates that cytotoxic doublets are approximately equal in terms of their relative efficacy and that, while the regimens do not differ in the rate of death due to treatment-related events, the regimens do have unique toxicity profiles. Differences in these toxicity profiles should continue to be the primary consideration when selecting treatment in advanced or metastatic NSCLC. Identifying the least toxic regimen and defining the role of non-platinum doublets, particularly in molecular selection strategies, will continue as important issues as new treatment approaches emerge. 
